Purpose: Current sequencing strategies can genetically solve 55-60% of inherited retinal degeneration (IRD) cases, despite recent progress in sequencing. This can partially be attributed to elusive pathogenic variants (PVs) in known IRD genes, including copy number variations (CNVs), which we believe are a major contributor to unsolved IRD cases.
INTRODUCTION:
Over two million people worldwide are affected by inherited retinal degenerations (IRDs), a family of blinding diseases characterized by progressive death and dysfunction of primarily rod and cone photoreceptors 1, 2 . Pathogenic variants (PVs) in over 270 genes have been associated with IRDs 3 , many of which were discovered recently by virtue of advances in sequencing technologies [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . However, despite substantial progress in genetic methodologies, current strategies can genetically solve only about 55-60% of IRD cases [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . The remaining missing diagnoses are in part due to new, yet to be discovered IRD genes. However, PVs in each new disease gene are rare, affecting a handful of IRD patients [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , suggesting that the missing genetic causality largely lies in the known IRD genes. A considerable proportion of these elusive PVs are due to structural variations (SVs) such as copy number variations (CNVs), or deep intronic variants that affect splicing 36, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] , which are not readily available from the standard output of targeted next generation sequencing (NGS) pipelines.
Our previous work analyzed 28 genetically unsolved families with whole exome sequencing (WES) and SNP and/or Comparative Genomic Hybridization (CGH) arrays, and showed that large deletions in known IRD genes were responsible for disease in five of the families (18% of unsolved cases) 41 . In this study we applied further bioinformatic analyses that permit detection of CNVs on the panel-based NGS Genetic Eye Disease (GEDi) diagnostic test that involves sequencing the exons of all known IRD disease genes 24, [50] [51] [52] . To assess the accuracy of CNV calling based on the NGS read depth we compared two algorithms, ExomeDepth 50 and gCNV 52 , with the SNP-array based approach 53 . A subset of the CNVs were subsequently validated by qPCR. In addition, we specifically searched for the Alu transposable element insertion in MAK, which is a common cause of IRD in people of Ashkenazi Jewish descent [54] [55] [56] . Applying these techniques improved the genetic diagnostic rate for IRD patients by 10%.
METHODS:

Ethical guidelines
The study was approved by the institutional review board at the Massachusetts Eye and Ear (Human Studies Committee MEE in USA) and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individuals on whom genetic testing and further molecular evaluations were performed.
Clinical evaluation
Patients included in the study were recruited and clinically examined at MEE.
Ophthalmic examination included best-corrected Snellen visual acuity, dynamic
Goldmann visual field testing, dark adaptation testing and full-field electroretinographic (ERG) testing with assessment of 0.5 Hz ERG amplitude and 30 Hz ERG amplitudes.
Genomic (g)DNA extraction and targeted sequencing
DNA was extracted from venous blood using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). All samples underwent Genetic Eye Disease test (GEDi) sequencing as described previously 24 . The GEDi version used in this study included 266 genes known to be associated with monogenic inherited retinal degenerations 3, 24 ( Supplementary Table S5 ). The capture libraries were sequenced on MiSeq (9 samples per run) or HiSeq (96 samples per run) NGS platforms (Illumina, San Diego, CA) as previously described 24 . The NGS data was analyzed using Genome Analysis Toolkit (GATK) 51 version 3 and annotated using the Variant Effect Predictor (VEP) tool 57 with additional annotations taken from the Genome Aggregation Database (GnomAD) Genomic Evolutionary Rate Profiling (GERP), SIFT, PolyPhen2 and retinal expression 58 . Rare variants were selected based on the minor allele frequency (MAF) in public databases of less than 0.3%. Variants were annotated based on the transcripts included in Supplementary Table S5 .
Exon 15 of RPGR transcript NM_001034853 (called RPGR ORF15) is not fully covered by the NGS and therefore it was PCR amplified and Sanger sequenced with previously established protocols (Supplementary Methods).
Copy Number Variation (CNV) Analysis
NGS read-depth Analysis: Copy number variation from NGS read-depth was inferred using ExomeDepth 50 and gCNV from the GATK version 4 51 . Samples from all of the MiSeq runs were processed together (193 samples) and HiSeq runs consisting of 96 samples each (except for one 48 sample run) were analyzed separately. In ExomeDepth analysis the samples were separated by gender, in gCNV analysis they were kept together. In the gCNV analyses, the GEDi-captured regions were padded by 250bp on each side and they were run in COHORT mode without external control samples. CNVs present in more than 15% samples were removed as they were considered to be either capture artifacts or common CNVs that would not lead to a rare Mendelian disorder. In addition, we removed CNVs in the OPN1LW gene and the OPN1MW gene, which were likely artifacts of poor mapping quality of the NGS reads.
SNP-Array:
Genomic DNA (gDNA) samples from probands were analyzed with whole-genome SNP microarray (HumanOmni2.5 BeadChip, Illumina) according to the manufacturer's instructions. The hybridized SNP arrays were analyzed using an array reader (iScan array scanner, Illumina) and the SNP calls were made with the genotyping module of the data analysis software (GenomeStudio, Illumina). Copy number variation from the SNP-array results was detected with PennCNV using default parameters and sex information 53 .
Quantitative real-time PCR
Deletions were validated using quantitative real-time PCR (qRT-PCR or qPCR) on gDNA with primers specific to sequences inside the presumed CNV and flanking the CNV ( Supplementary Table S1 ). The amplification was normalized to the ZNF80 reference gene. For each qPCR reaction 5 ng of gDNA, 200 nM of each primer and 10 µl of Fast SYBR Green master mix (Life Technologies, Grand Island, NY) were used.
The amplification was performed in a qPCR system (Stratagene Mx3000P®, Agilent Technologies) using the standard thermo-cycling program: 95°C for 3 minutes, 40 cycles of 95°C for 20 seconds, 60°C for 1 minute followed by a melting curve. Each sample was assayed in triplicate. Relative changes in genomic sequence abundance were calculated using the 2 -ddC T method 59 , and error was calculated using standard propagation of errors. Data was visualized using custom R scripts.
RESULTS:
A cohort of 500 IRD patients was sequenced with the targeted NGS panel -Genetic Eye Disease test (GEDi) 24 and analyzed with a standard NGS analysis pipeline detecting single nucleotide variants (SNVs) and small insertions and deletions (indels) 51 to find likely pathogenic variants leading to retinal degeneration. SNVs and small indels likely leading to disease were found in 279 IRD subjects (55.8% of the total cohort),
where PVs in USH2A (11.8%), RPGR (4%) and EYS (4%) were the most common causes of disease ( Figure 1 , Supplementary Table S2 ). In addition, MAK-Alu insertion was detected in seven patients by analyzing the NGS sequence reads 60 .
CNV predictions using NGS data
Additional analysis of the NGS sequence data to detect copy number variations was performed with ExomeDepth 50 and gCNV 52 Supplementary Table S3 ).
Most of the CNVs detected in this project were easily interpretable as they were either homozygous deletions, heterozygous deletions coupled with a deleterious allele in trans or heterozygous deletions in the known haploinsufficiency gene PRPF31 61 . However, there were a few examples of more unusual CNV contributions to disease etiology.
In two patients we detected two non-consecutive heterozygous deletions, which are thought to be due to deletions in trans (e.g. EYS deletions in subject 121-182 (simplex RP), or PCDH15 deletions in subject OGI635_001299 (Usher Syndrome), Supplementary Table S3 , Supplementary Figure S1 ). Unfortunately, due to lack of samples from family members and a large distance between the deletions (0.86 and 0.51 Mb), the phase of these deletions could not be confirmed.
Subject OGI655_001331 presented with inherited macular degeneration, historically known as Stargardt Disease, and carried a heterozygous deletion of almost the entire ABCA4 gene (exons 1-40). On closer examination, it was revealed that the same subject also carried a common hypomorphic missense change p.Asn1868Ile, which due to its high allele frequency (AF=0.042 in GnomAD) was overlooked during the initial analysis. The p.Asn1868Ile missense in trans with a deleterious missense variant or loss of function allele was shown to lead to a late onset macular degeneration 62 We identified five duplications ( Figure 1B , Supplementary Table S3) 
Comparison of CNVs predicted by NGS analysis versus SNP-array analysis
To assess the diagnostic performance of ExomeDepth and gCNV, we compared them with the SNP-Array-based detection of CNVs using the PennCNV algorithm 53 potentially solving CNVs. All predicted solving CNVs were then tested by qPCR to determine if they were confirmed true positives (Figure 2A, B, Supplementary Figure   S1A , B). Of the three methods used, gCNV showed the best performance with 44 out of 52 predictions that validated (positive predictive value, or PPV equal to 85%) compared to ExomeDepth (37/52, PPV=71%) and SNP-Array (25/31, PPV=81%) ( Table 1) .
Intersection of any two algorithms increased the PPV with a considerable decrease of sensitivity ( Table 1 ). The gCNV algorithm alone predicted all of the true positive CNVs detected in this study (Figure 2A ). False positive rate was the highest (29%) in ExomeDepth ( Figure 2B ).
Depending on the technique used, the predicted sizes of the validated CNVs ranged from 59bp to 249kb (ExomeDepth), 619bp to 249kb (gCNV) and 2.2kb to1.6Mb (SNParray) ( Figure 2C ). Since NGS-based methods only investigate regions covered by the capture kit (i.e. IRD gene exons), and the SNP-Array covers the genome in a more uniform fashion, the sizes of large CNVs predicted are probably more accurately represented by the SNP-Array. In this study, we did not attempt to map all the CNV breakpoints, however we validated the CNVs with multiple qPCR primers inside and outside of the predicted deletions (Supplementary Figure S1 ).
Further, we wanted to investigate the reasons for the SNP-array failing to detect 19 true CNVs that were predicted by gCNV. The most plausible reason is that the CNV is not covered by the sufficient number of SNPs on the array because it is too small or it is in a region that is poorly represented on the array. First, we compared the sizes of the CNVs predicted by gCNV that were validated by the SNP-Array (SA+ve) and that were not validated by the SNP-Array (SNP-ve) ( Figure 2D ). As expected CNVs that were not predicted by the SNP-Array were on average smaller (median = 772bp, mean = 6.5kb) than the CNVs that were also validated by the array (median = 17kb, mean = 49kb).
None of the twelve CNVs that were below 1kb had sufficient number of SNPs (at least three) on the Omni2.5 Array to be detected by this method. Of the remaining seven larger CNVs (~7 -44kb) that were not detected by the SNP-Array, most had sufficient number of SNPs in the interval ( Supplementary Table S3 ), therefore, failure to detect them by the SNP array was due to other undetermined experimental or analytical reasons.
Assessment of gCNV prediction scores
In the original analysis of the gCNV output we did not apply any quality filters, as the primary constraint on the data was whether a CNV fulfilled our "potentially solving"
criteria. As such, we noticed that some low-quality predictions validated by qPCR.
However, an agnostic search for true positive CNVs requires quality filters to remove false predictions, even at the expense of throwing out true positives. Therefore, we removed CNV predictions that were present in greater than 15% samples and CNVs from the opsin gene locus on chromosome X, which due to poor NGS mapping quality generated a high rate of likely false positive CNVs. Analysis of the 500 sample cohort with this filtering yielded 423 CNVs detected in 152 patients, of which 44 patients were solved with a CNV (validated by qPCR), 75 were solved with an SNV or small indel and 37 patients remained unsolved. Next, using the qPCR validated CNV predictions, we compared the different quality score metrics generated by gCNV ( Figure 3 ) in order to choose one for a quality score cut-off. We settled on using the score of QA > 30 51 . This cut-off included three of nine falsely predicted CNVs and missed three of 47 true positive predictions (PPV=0.93) ( Figure 3 ).
Assessment of frequency of patients with single likely pathogenic alleles in a recessive IRD gene
To assess how likely it is that the remaining genetically unsolved patients carry elusive pathogenic variants in already known IRD genes, we first evaluated how many unsolved patients have known pathogenic variants or new loss of function variants in recessive IRD disease genes, including CNVs. Of the 170 unsolved subjects, 38 carried stop, frameshift or essential splice-site variants and four subjects carried known pathogenic missense alleles. In addition, ten patients carried likely pathogenic CNVs ( Supplementary Table S4 ). Altogether, we estimated that at least 30.6% of the unsolved patients (10.4% of the overall cohort) carried a single likely pathogenic allele in a recessive IRD gene.
DISCUSSION
The results reported here indicate that CNVs contribute significantly to the genetic causality of IRDs, and that NGS based CNV detection methods outperform SNP array based CNV detection methods. Of the 500 patients whose genetic cause of disease was investigated by panel based NGS testing (GEDi) 66 , likely disease-causing CNVs were identified in 44 or 8.8% of cases. In 279 cases (55.8%) the disease could be explained by the likely pathogenic SNVs and small indels that are generated by the standard NGS analysis pipeline 51 . The only other structural variant that was investigated was a known
Alu insertion in exon 9 of MAK [54] [55] [56] , which was present in seven cases (1.4%), agreeing closely with the previously reported frequency of 1.2% 54 .
The majority of the CNVs were heterozygous or homozygous deletions, ranging from single exon deletions to whole gene deletions. Three large deletions in two genes (MERTK and TRPM1) were in regions prone to the non-alleleic homologous recombination (NAHR), which is the most likely mechanism of their occurrence 41 .
Analysis of all CNVs reported in IRD genes performed by Van Schil and colleagues indicated that gene size, followed by the number of LINE and LTR repeats is the biggest predictor for a gene to be prone to CNVs 67 67 .
Searching for genetic causes of Mendelian diseases is commonly performed via a serial approach: first by looking for causal SNVs and small indels, and second moving on to more complex analyses such as CNV predictions. We propose that such causality searches are better undertaken in tandem because certain variants may falsely appear as homozygous but in fact they are in trans with a large deletion. This distinction is particularly important when a hypomorphic variant is involved, as in the case of p.Asn1868Ile in ABCA4 discovered in trans with a large deletion in subject OGI655_001331. The p.Asn1868Ile variant in a homozygous state is not considered as pathogenic, however when paired in trans with a severe pathogenic variant it has been shown to be causal 62 . Therefore, only when considered together, the heterozygous deletion of nearly the entire gene with a heterozygous p.Asn1868Ile variant led to a conclusive genetic diagnosis.
Of 44 patients with CNVs, only five carried likely causal duplications, which may be a bias based on the fact that duplications are more difficult to detect, interpret and validate. All but one of the duplications is thought to result in a loss of function allele.
Duplication of OFD1 exons 6-15, is predicted to duplicate an internal 414 amino-acids of the protein and lead to a partially functioning OFD1 protein, resulting in a decreased spectrum of disease in subject OGI2829_004414, who apart from retinal disease has possible cognitive dysfunction and a history of renal failure, which resulted in transplantation. Variants in OFD1 may lead to a spectrum of phenotypes from an x-linked dominant oral-facial-digital type 1 syndrome, with ciliopathy phenotype in females and embryonic lethal in males, x-linked recessive Joubert syndrome to non-syndromic IRD, depending on where the variant is located 39, 65, 68 , however to our knowledge no causal duplications in OFD1 have been reported to date.
NGS based CNV prediction with the gCNV algorithm showed considerable advantage over more traditional SNP-array based prediction, as it had an increased diagnostic rate (44 vs 25 validated CNVs) and a higher positive predictive value (85% vs 81%). The major reason for this is that on average, NGS based algorithms could detect smaller CNVs as they were not restricted by the availability of SNPs in that region. In our study, all of the validated CNVs detected by the SNP array were also detected by the gCNV algorithm, therefore this method is an adequate replacement of the SNP-array based CNV predictions. Another accurate method of CNV detection is microarray-based comparative genomic hybridization (Array-CGH), which can be designed to cover intronic and exonic regions, as in the case of the IRD custom array (arrEYE) 47 . However, this method requires an additional wet-lab assay to be applied to the samples that had already undergone NGS, which may be unnecessary if the CNVs can be detected by a robust NGS-based algorithm. In this study we chose to use qPCR on genomic DNA as a validation of the CNVs, as this is a cost-effective and easily accessible method widely applied in many labs, however other assays such as Multiplex Ligation-dependent Probe Amplification (MLPA) 69 or droplet PCR 70 can also be used. Accurate characterization of CNVs can also be achieved by targeted locus amplification 67 .
In a genetic diagnostic setting, filtering based on CNV prevalence in the cohort (high prevalence could indicate likely capture artifact, or common CNV), CNV frequency per sample (high frequency could indicate low gDNA quality) and gCNV quality scores will aid in assessing the likelihood of a given CNV being true positive. In this study, we used experimental results to establish hard thresholds on gCNV predictions (discarding CNVs that appeared in >15% of the cohort, discarding CNVs with a QA < 30), to reduce predicted CNVs to a subset with a higher probability of being true genetic variants. In future studies, more sophisticated methods can be used, such as creating a scoring method which considers multiple factors, similar to the guidelines recommended for sequence variant curation from ACMG 71 . Taking into account the population-level frequency of CNVs using publicly available datasets will also be crucial in establishing the pathogenicity of the CNVs 67,72 .
In conclusion, our rate of discovery for likely solving variants in IRD patients has increased from 55.8% to 65.8% by including information from CNVs and MAK-Alu insertions. This represents a significant improvement in solving genetic cases, consistent with or higher than in previous studies 47, 48, [73] [74] [75] Note that in general, duplications were predicted less often, and were on average larger in size than predicted deletions. D) Comparison of the gCNV predicted sizes of validated CNVs that were also predicted by the SNP array (gCNV SA+ve) versus the gCNV predicted size of validated CNVs that were not predicted by the SA (gCNV SAve). 
